WO2022173042A1 - サイトカインストーム抑制用医薬組成物 - Google Patents
サイトカインストーム抑制用医薬組成物 Download PDFInfo
- Publication number
- WO2022173042A1 WO2022173042A1 PCT/JP2022/005709 JP2022005709W WO2022173042A1 WO 2022173042 A1 WO2022173042 A1 WO 2022173042A1 JP 2022005709 W JP2022005709 W JP 2022005709W WO 2022173042 A1 WO2022173042 A1 WO 2022173042A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lps
- syndrome
- administered
- group
- administered group
- Prior art date
Links
- 206010052015 cytokine release syndrome Diseases 0.000 title claims abstract description 73
- 206010050685 Cytokine storm Diseases 0.000 title claims abstract description 50
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 58
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 36
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 36
- 230000017306 interleukin-6 production Effects 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 235000013305 food Nutrition 0.000 claims description 14
- 230000006433 tumor necrosis factor production Effects 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 7
- AEDDIBAIWPIIBD-ZJKJAXBQSA-N mangiferin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(OC=2C(=CC(O)=C(O)C=2)C2=O)C2=C1O AEDDIBAIWPIIBD-ZJKJAXBQSA-N 0.000 abstract description 93
- YWQSXCGKJDUYTL-UHFFFAOYSA-N Mangiferin Natural products CC(CCC=C(C)C)C1CC(C)C2C3CCC4C(C)(C)CCCC45CC35CCC12C YWQSXCGKJDUYTL-UHFFFAOYSA-N 0.000 abstract description 49
- 229940043357 mangiferin Drugs 0.000 abstract description 49
- 208000032672 Histiocytosis haematophagic Diseases 0.000 abstract description 25
- 208000025721 COVID-19 Diseases 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 15
- 206010040047 Sepsis Diseases 0.000 abstract description 14
- 208000004987 Macrophage activation syndrome Diseases 0.000 abstract description 13
- 208000024908 graft versus host disease Diseases 0.000 abstract description 13
- 206010022000 influenza Diseases 0.000 abstract description 13
- 208000011200 Kawasaki disease Diseases 0.000 abstract description 12
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 abstract description 12
- 206010047115 Vasculitis Diseases 0.000 abstract description 12
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 abstract description 12
- 238000002560 therapeutic procedure Methods 0.000 abstract description 12
- 208000001106 Takayasu Arteritis Diseases 0.000 abstract description 11
- 208000004732 Systemic Vasculitis Diseases 0.000 abstract description 10
- 230000034994 death Effects 0.000 abstract description 7
- 231100000517 death Toxicity 0.000 abstract description 7
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 abstract description 5
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 abstract description 5
- 201000000028 adult respiratory distress syndrome Diseases 0.000 abstract description 5
- 208000009190 disseminated intravascular coagulation Diseases 0.000 abstract description 5
- 208000011580 syndromic disease Diseases 0.000 abstract description 5
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract description 4
- 206010009192 Circulatory collapse Diseases 0.000 abstract description 4
- 208000034486 Multi-organ failure Diseases 0.000 abstract description 4
- 208000010718 Multiple Organ Failure Diseases 0.000 abstract description 4
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 abstract description 4
- 241001678559 COVID-19 virus Species 0.000 abstract description 3
- 239000002158 endotoxin Substances 0.000 description 86
- 229920006008 lipopolysaccharide Polymers 0.000 description 86
- 108020004999 messenger RNA Proteins 0.000 description 30
- 108090001005 Interleukin-6 Proteins 0.000 description 29
- 102000004889 Interleukin-6 Human genes 0.000 description 29
- 229940100601 interleukin-6 Drugs 0.000 description 29
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- 241000699666 Mus <mouse, genus> Species 0.000 description 23
- 210000003719 b-lymphocyte Anatomy 0.000 description 23
- 210000002540 macrophage Anatomy 0.000 description 23
- 230000014509 gene expression Effects 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 239000000543 intermediate Substances 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- 238000002965 ELISA Methods 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 description 11
- 208000014752 hemophagocytic syndrome Diseases 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 10
- 230000028327 secretion Effects 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 230000001629 suppression Effects 0.000 description 8
- SGQWQUYTTYVSBS-UHFFFAOYSA-N 1,3,6,7-tetramethoxyxanthen-9-one Chemical compound COC1=C(OC)C=C2C(=O)C3=C(OC)C=C(OC)C=C3OC2=C1 SGQWQUYTTYVSBS-UHFFFAOYSA-N 0.000 description 7
- 108010057466 NF-kappa B Proteins 0.000 description 7
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 238000008157 ELISA kit Methods 0.000 description 6
- 239000012980 RPMI-1640 medium Substances 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 5
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- SYEQFHMVMNCKSY-UHFFFAOYSA-N (2-hydroxy-4,5-dimethoxyphenyl)-(2,4,6-trimethoxyphenyl)methanone Chemical compound OC1=C(C=C(C(=C1)OC)OC)C(=O)C1=C(C=C(C=C1OC)OC)OC SYEQFHMVMNCKSY-UHFFFAOYSA-N 0.000 description 4
- LKUDPHPHKOZXCD-UHFFFAOYSA-N 1,3,5-trimethoxybenzene Chemical compound COC1=CC(OC)=CC(OC)=C1 LKUDPHPHKOZXCD-UHFFFAOYSA-N 0.000 description 4
- KVZUCOGWKYOPID-UHFFFAOYSA-N 2,4,5-Trimethoxybenzoic acid Chemical compound COC1=CC(OC)=C(C(O)=O)C=C1OC KVZUCOGWKYOPID-UHFFFAOYSA-N 0.000 description 4
- JEPXZNXBEFYVOZ-UHFFFAOYSA-N 2,4,5-trimethoxybenzoyl chloride Chemical compound COC1=CC(OC)=C(C(Cl)=O)C=C1OC JEPXZNXBEFYVOZ-UHFFFAOYSA-N 0.000 description 4
- 108700039887 Essential Genes Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- ZHTQCPCDXKMMLU-UHFFFAOYSA-N norathyriol Chemical compound OC1=C(O)C=C2C(=O)C3=C(O)C=C(O)C=C3OC2=C1 ZHTQCPCDXKMMLU-UHFFFAOYSA-N 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000002194 synthesizing effect Effects 0.000 description 4
- VDZOOKBUILJEDG-UHFFFAOYSA-M tetrabutylammonium hydroxide Chemical compound [OH-].CCCC[N+](CCCC)(CCCC)CCCC VDZOOKBUILJEDG-UHFFFAOYSA-M 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 101001076414 Mus musculus Interleukin-6 Proteins 0.000 description 3
- 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 239000002274 desiccant Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- XJSFLOJWULLJQS-NGVXBBESSA-N josamycin Chemical compound CO[C@H]1[C@H](OC(C)=O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](OC(=O)CC(C)C)[C@](C)(O)C2)[C@@H](C)O1 XJSFLOJWULLJQS-NGVXBBESSA-N 0.000 description 2
- 229960004144 josamycin Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- JNELGWHKGNBSMD-UHFFFAOYSA-N xanthone Chemical group C1=CC=C2C(=O)C3=CC=CC=C3OC2=C1 JNELGWHKGNBSMD-UHFFFAOYSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 101100508533 Drosophila melanogaster IKKbeta gene Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 102100027619 Histidine-rich glycoprotein Human genes 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 208000001940 Massive Hepatic Necrosis Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 239000004187 Spiramycin Substances 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000004143 Waterhouse-Friderichsen Syndrome Diseases 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- YHASWHZGWUONAO-UHFFFAOYSA-N butanoyl butanoate Chemical group CCCC(=O)OC(=O)CCC YHASWHZGWUONAO-UHFFFAOYSA-N 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- IUNMPGNGSSIWFP-UHFFFAOYSA-N dimethylaminopropylamine Chemical compound CN(C)CCCN IUNMPGNGSSIWFP-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 108010044853 histidine-rich proteins Proteins 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- XJSFLOJWULLJQS-UHFFFAOYSA-N leucomycin A3 Natural products COC1C(OC(C)=O)CC(=O)OC(C)CC=CC=CC(O)C(C)CC(CC=O)C1OC1C(O)C(N(C)C)C(OC2OC(C)C(OC(=O)CC(C)C)C(C)(O)C2)C(C)O1 XJSFLOJWULLJQS-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- -1 patches Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019685 rice crackers Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960001294 spiramycin Drugs 0.000 description 1
- 229930191512 spiramycin Natural products 0.000 description 1
- 235000019372 spiramycin Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Definitions
- the present invention relates to COVID-19, cytokine release syndrome, CAR (chimeric antigen receptor)-T therapy-induced cytokine release syndrome, sepsis, systemic inflammatory response syndrome, hemophagocytic syndrome, macrophage activation syndrome, influenza, GVHD (Graft-versus - Compositions, pharmaceutical compositions, and food compositions that are effective in preventing, treating, or alleviating cytokine storm, which is a cause of death in host disease (graft versus host disease), systemic vasculitis, Kawasaki disease, Takayasu arteritis, etc. and agents.
- CAR chimeric antigen receptor
- COVID-19 (abbreviation for Corona virus disease 2019) is a disease caused by SARS-CoV-2 (acronym for Severe acute respiratory syndrome corona virus 2). Critically ill patients with this disease develop acute respiratory distress syndrome and acute lung injury.
- TNF ⁇ Tumor necrosis factor ⁇
- IL-6 interleukin 6
- Inflammatory cytokines such as TNF ⁇ and IL-6 are secreted from macrophages, B cells, monocytes, etc., and are associated with COVID-19, cytokine release syndrome, cytokine release syndrome by CAR-T therapy, sepsis, systemic inflammatory response syndrome, hemophagocytosis. It is released in large amounts by diseases such as syndrome, macrophage activation syndrome, influenza, GVHD, systemic vasculitis, Kawasaki disease, and Takayasu arteritis.
- cytokine storm causes acute respiratory distress syndrome, disseminated intravascular coagulation syndrome, acute circulatory failure, multiple organ failure, and the like, and is one of the causes of death.
- NIK is a serine/threonine kinase that plays a role in both the canonical and non-canonical NF- ⁇ B pathways, but is essential in the non-canonical NF- ⁇ B signaling pathway and phosphorylates IKK ⁇ . This partially degrades NF- ⁇ Bp100 and releases NF- ⁇ Bp52. By forming a heterodimer with RelB, NF- ⁇ Bp52 translocates into the nucleus and expresses inflammatory cytokine genes such as TNF ⁇ and IL-6.
- the canonical NF- ⁇ B pathway activates the IKK ⁇ , IKK ⁇ , and IKK ⁇ complexes to form heterodimers of NF- ⁇ Bp65 and NF- ⁇ Bp50, which translocate into the nucleus, leading to TNF ⁇ and IL- Regulates gene expression of inflammatory cytokines such as 6.
- LPS Lipopolysaccharide
- NF- ⁇ B pathway classical and non- Promoting activation of the canonical NF- ⁇ B pathway promotes the production of inflammatory cytokines such as TNF ⁇ and IL-6 in B cells and macrophages.
- drugs that suppress classical and non-classical NF- ⁇ B pathway activation by NIK via LPS etc. and inhibit the production of inflammatory cytokines are COVID-19, cytokine release syndrome, CAR-T therapy Cytokine release syndrome, sepsis, systemic inflammatory response syndrome, hemophagocytic syndrome, macrophage activation syndrome, influenza, GVHD, systemic vasculitis, Kawasaki disease, acute respiratory distress syndrome in Takayasu arteritis, disseminated intravascular coagulation syndrome, Acute circulatory failure, suppression of multiple organ failure, COVID-19, cytokine release syndrome, cytokine release syndrome by CAR-T therapy, sepsis, systemic inflammatory response syndrome, hemophagocytic syndrome, macrophage activation syndrome, influenza, GVHD, systemic It may reduce mortality in vasculitis, Kawasaki disease, Takayasu arteritis, etc.
- Cytokine storm is a symptom that also occurs in other diseases.
- Patent Document 1 discloses a cytokine storm inhibitor containing histidine-rich glycoprotein as an active ingredient.
- the disclosed cytokine storm inhibitor has an action of suppressing at least two or more cytokines selected from IL-6, TNF- ⁇ , and IL-10.
- Patent Document 2 Japanese Patent Laid-Open No. 2012-20953 describes spiramycin or josamycin (leucomycin A3), or a pharmaceutically acceptable salt thereof as an active ingredient for prevention of fulminant inflammation and/or Or therapeutic agents are disclosed.
- This prophylactic and/or therapeutic agent for fulminant inflammation is considered to be an agent for prophylaxis and/or treatment of fulminant inflammation caused by influenza infection (preferably H5N1 or H1N1).
- agents that suppress canonical and non-canonical NF- ⁇ B pathway activation by NIK may be useful in COVID-19, cytokine release syndrome , Cytokine storm caused by CAR-T therapy, sepsis, systemic inflammatory response syndrome, hemophagocytic syndrome, macrophage activation syndrome, influenza, GVHD, systemic vasculitis, Kawasaki disease, Takayasu arteritis, etc.
- it is highly expected to reduce the number of deaths by avoiding acute respiratory distress syndrome, disseminated intravascular coagulation, acute circulatory failure, multiple organ failure, and the like.
- the present inventors searched for a material that suppresses the cytokine storm, found that substances having a xanthone skeleton (including new substances) were effective, and completed the present invention.
- the pharmaceutical composition for suppressing cytokine storm according to the present invention is characterized by containing at least one of the compounds of formulas (1) to (4) as an active ingredient.
- the pharmaceutical composition for suppressing cytokine storm according to the present invention is COVID-19, cytokine release syndrome, cytokine release syndrome caused by CAR-T therapy, sepsis, systemic inflammatory response syndrome, hemophagocytic syndrome, macrophage activation syndrome, influenza, GVHD. , systemic vasculitis, Kawasaki disease, Takayasu's arteritis, etc., which is one of the causes of death.
- cytokine release syndrome COVID-19, cytokine release syndrome, cytokine release syndrome due to CAR-T therapy, sepsis, systemic inflammatory response syndrome, hemophagocytic syndrome, macrophage activation syndrome, influenza, GVHD, systemic vasculitis, Kawasaki disease, Takayasu arteritis Improving the cytokine storm caused by such factors will also improve the patient's survival rate. Furthermore, since the cytokine storm inhibitor according to the present invention can be administered orally, it contributes to the improvement of the tight medical field.
- 1 is a graph showing the results of examining the ability of each compound to suppress TNF ⁇ mRNA production when mouse B cells were stimulated with LPS.
- 1 is a graph showing the results of examining the ability of each compound to suppress IL-6 mRNA production when mouse B cells were stimulated with LPS.
- 1 is a graph showing the results of examining the ability of each compound to suppress TNF ⁇ mRNA production when mouse macrophages were stimulated with LPS.
- 1 is a graph showing the results of examining the ability of each compound to suppress IL-6 mRNA production when mouse macrophages were stimulated with LPS.
- 1 is a graph showing the results of examining the TNF ⁇ secretion inhibitory effect of each compound when mouse B cells were stimulated with LPS.
- 1 is a graph showing the results of examining the IL-6 secretion inhibitory effect of each compound when mouse B cells were stimulated with LPS.
- 1 is a graph showing the results of examining the TNF ⁇ secretion inhibitory effect of each compound when mouse macrophages were stimulated with LPS.
- 1 is a graph showing the results of examining the IL-6 secretion inhibitory effect of each compound when mouse macrophages were stimulated with LPS.
- Fig. 10 is a graph showing the results of examining the survival rate 48 hours after administration of each reagent to mice followed by administration of LPS.
- 2 is a graph showing the amount of TNF ⁇ produced in the serum of mice administered with each reagent and then LPS administered 2 hours later.
- 2 is a graph showing the amount of IL-6 produced in the serum of mice administered with each reagent and then LPS administered 2 hours later.
- cytokine storm suppression means exhibiting the effect of suppressing the production of TNF ⁇ or IL-6.
- the compounds according to the present invention are represented by formulas (1) to (4) having a xanthone skeleton.
- the "compound according to the present invention” may refer to at least one of the following four compounds.
- Formula (1) is 1,3,6,7-tetrahydroxyxanthone, hereinafter referred to as "Noratriol".
- Norachiliol is a known substance represented by CAS number 3542-72-1.
- Formula (2) is 1,2′,3′,4′,6′-penta-O-propionyl mangiferin, hereinafter referred to as “mangiferin 8a”.
- Formula (3) is 2′,3′,4′,6′-tetra-O-propionyl mangiferin (hereinafter referred to as “M9”).
- Formula (4) is 2′,3′,4′,6′-tetra-O-butyrylmangiferin (hereinafter referred to as “M14”).
- M14 2′,3′,4′,6′-tetra-O-butyrylmangiferin
- R 1 to R 8 represent functional groups.
- These compounds according to the present invention can be used as pharmaceutical compositions for suppressing cytokine storm. Its mechanism of action is thought to be that it inhibits NIK in the intracellular transduction pathway and suppresses NF- ⁇ B from IKK.
- the compound according to the present invention like mangiferin, is a relatively low-molecular-weight compound, is highly soluble in water, and can be taken orally.
- the pharmaceutical composition for suppressing cytokine storm according to the present invention contains at least one of the above four compounds according to the present invention as an active ingredient. It may also contain other pharmaceutically acceptable ingredients.
- the pharmaceutical composition for suppressing cytokine storm according to the present invention can exert its effect by oral administration. Therefore, it can be provided as an internal medicine.
- a powdery pharmaceutical composition for suppressing cytokine storm can be formulated into capsules, granules, powders, tablets, and the like, and provided.
- additives such as binders, lubricants, disintegrants, coloring agents, flavoring agents, preservatives, antioxidants, and stabilizers are added to prepare capsules, granules, powders, and tablets. It can be manufactured by a conventional method.
- the cytokine storm suppressing pharmaceutical composition according to the present invention can be administered by intravenous, subcutaneous, or intramuscular injection.
- the pharmaceutical composition according to the present invention may be formulated into external preparations such as liquids, ointments, creams, gelling agents, patches, and aerosols, and administered parenterally.
- external preparations such as liquids, ointments, creams, gelling agents, patches, and aerosols, and administered parenterally.
- water, a lower alcohol, a solubilizer, a surfactant, an emulsion stabilizer, a gelling agent, an adhesive, and other necessary base ingredients can be blended.
- Additives such as vasodilating agents, adrenocortical hormones, keratolytic agents, moisturizing agents, bactericidal agents, antioxidants, cooling agents, fragrances, and pigments may be added as appropriate.
- the compound according to the present invention can be provided as a food composition or agent. That is, even if the compound according to the present invention is ingested as a food composition, it exhibits the same effect as the pharmaceutical composition for suppressing cytokine storm according to the present invention.
- the agent includes supplements and additives.
- Food compositions or agents include, for example, candy, gum, jelly, biscuits, cookies, rice crackers, bread, noodles, fish and livestock meat products, tea, soft drinks, coffee drinks, milk drinks, whey drinks, lactic acid beverages,
- foods with health claims such as foods with specified health uses and foods with nutrient function claims stipulated in the food with health claims system of the Ministry of Health, Labor and Welfare.
- dietary supplements (supplements), feeds, food additives, etc. are also included in processed foods or agents.
- the food composition according to the present invention can be prepared by adding the above four compounds to the ingredients of these food compositions or agents.
- the addition of the compound according to the present invention to the food composition or agent may be said to be added as an active ingredient.
- the food composition or agent according to the present invention can be said to be a food composition or agent labeled as being for cytokine storm suppression.
- Mangiferin 8a was synthesized as follows. 1,3,2′,3′,4′,6,6′,7-octa-O-propionylmangiferin (M7) (5.06 g, 5.68 mmol), ammonium acetate (6.7 g, 87.0 mmol) ), methanol (160 mL) and water (20 mL) was stirred at room temperature for 6 hours. Methanol was distilled off from the reaction solution by concentration under reduced pressure, and the residue was diluted with ethyl acetate (100 mL). The mixture was washed successively with water and saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified using column chromatography [CHCl 3 /CH 3 OH (20:1)] to give the title compound (3.89 g 95%) as a pale yellow solid.
- Mangiferin 8a is represented by formula (2).
- Norachiliol was synthesized according to the method of Non-Patent Document 1.
- Norachiliol is a known substance represented by CAS No. 3542-72-1 and is commercially available, so it may be purchased.
- Norachiliol was synthesized as follows. That is, 2,4,5-trimethoxybenzoic acid (Compound II) was treated with thionyl chloride according to the method described in the literature (Non-Patent Document 1) to obtain 2,4,5-trimethoxybenzoic acid chloride (Compound III). rice field. Next, the obtained compound (compound III) and 1,3,5-trimethoxybenzene (compound IV) undergo Friedel-Crafts reaction to give 2-hydroxy-2′,4,4′,5,6′- Pentamethoxybenzophenone (Compound V) was obtained.
- the extract was washed with saturated brine, dried over anhydrous sodium sulfate, filtered through a folded filter paper to remove the desiccant, and the filtrate was evaporated under reduced pressure to obtain a crude product.
- Example 1 Effect of suppressing TNF ⁇ mRNA expression in B cells Using mouse B cells, the inhibitory effects of compounds on TNF ⁇ mRNA expression involved in cytokine storm were examined.
- Mouse B cells were cultured in RPMI1640 medium for one day. After that, 10 ⁇ M mangiferin 8a, 10 ⁇ M norathyrilol, 1 ⁇ M M9 and 1 ⁇ M M14 were added to the B cells, cultured for 1 day, 10 ⁇ g/mL LPS was added, and cultured for 4 hours. After culturing for 4 hours, the cells were collected, RNA was extracted, and TNF ⁇ mRNA expression was measured by Real Time PCR. The results are shown in FIG.
- the horizontal axis shows the treatment of each drug
- the vertical axis shows the TNF ⁇ for mRNA of the housekeeping gene GAPDH (glyceraldehyde-3-phosphate dehydrogenase). It shows the ratio of mRNA of .
- a control was prepared by adding only 0.5% DMSO in PBS used for dissolving the reagent. 10 ⁇ g/mL LPS was administered to the LPS administration group, LPS and mangiferin 8a were administered together to the mangiferin 8a administration group, LPS and norachiryol were administered to the norachiriol administration group, LPS and M9 were administered together.
- a group administered with LPS and M14 is called an M9-administered group
- a group administered with LPS and M14 in combination is called an M14-administered group.
- the LPS-administered group showed enhanced expression of TNF ⁇ mRNA. This reproduces the state of causing a cytokine storm.
- a decrease in LPS-induced TNF ⁇ mRNA expression was confirmed in all of the mangiferin 8a-administered group, the noracilliol-administered group, the M9-administered group, and the M14-administered group.
- Example 2 Effect of suppressing IL-6 mRNA expression in B cells Mouse B cells were used to examine the compound's suppression of IL-6 mRNA expression involved in cytokine storm. The experimental procedure is the same as in Example 1. The results are shown in FIG.
- the horizontal axis indicates the treatment with each drug
- the vertical axis indicates the ratio of IL-6 mRNA to the housekeeping gene GAPDH mRNA.
- a control was prepared by adding only 0.5% DMSO in PBS used for dissolving the reagent. 10 ⁇ g/mL LPS was administered to the LPS administration group, LPS and mangiferin 8a were administered together to the mangiferin 8a administration group, LPS and norachiryol were administered to the norachiriol administration group, LPS and M9 were administered together.
- a group administered with LPS and M14 is called an M9-administered group, and a group administered with LPS and M14 in combination is called an M14-administered group.
- the LPS-administered group showed enhanced expression of IL-6 mRNA. This reproduces the state of causing a cytokine storm.
- a decrease in the expression of IL-6 mRNA was confirmed in all of the mangiferin 8a-administered group, the noracliol-administered group, the M9-administered group, and the M14-administered group.
- Example 3 Effect of suppressing TNF ⁇ mRNA expression in macrophages Using mouse macrophages, the inhibitory effects of compounds on TNF ⁇ mRNA expression involved in cytokine storm were examined.
- Mouse macrophages were cultured in RPMI1640 medium for one day. After that, 10 ⁇ M mangiferin 8a, 10 ⁇ M noratilol, 1 ⁇ M M9 and 1 ⁇ M M14 were added to the macrophages, cultured for 1 day, 10 ⁇ g/mL LPS was added, and cultured for 4 hours. After culturing for 4 hours, the cells were collected, RNA was extracted, and TNF ⁇ mRNA expression was measured by Real Time PCR. The results are shown in FIG.
- the horizontal axis indicates the treatment with each drug
- the vertical axis indicates the ratio of TNF ⁇ mRNA to GAPDH mRNA, which is a housekeeping gene.
- a control was prepared by adding only 0.5% DMSO in PBS used for dissolving the reagent. 10 ⁇ g/mL LPS was administered to the LPS administration group, LPS and mangiferin 8a were administered together to the mangiferin 8a administration group, LPS and norachiryol were administered to the norachiriol administration group, LPS and M9 were administered together.
- a group administered with LPS and M14 is called an M9-administered group, and a group administered with LPS and M14 in combination is called an M14-administered group.
- the LPS-administered group showed enhanced expression of TNF ⁇ mRNA. This reproduces the state of causing a cytokine storm.
- a decrease in LPS-induced TNF ⁇ mRNA expression was confirmed in all of the mangiferin 8a-administered group, the noracilliol-administered group, the M9-administered group, and the M14-administered group.
- Example 4 Effect of suppressing IL-6 mRNA expression in macrophages
- Mouse macrophages were used to examine the suppression of IL-6 mRNA expression involved in cytokine storm by compounds.
- the experimental procedure is the same as in Example 3. The results are shown in FIG. Referring to FIG. 4, the horizontal axis indicates the treatment with each drug, and the vertical axis indicates the ratio of IL-6 mRNA to the housekeeping gene GAPDH mRNA.
- a control was prepared by adding only 0.5% DMSO in PBS used for dissolving the reagent. 10 ⁇ g/mL LPS was administered to the LPS administration group, LPS and mangiferin 8a were administered together to the mangiferin 8a administration group, LPS and norachiryol were administered to the norachiriol administration group, LPS and M9 were administered together.
- a group administered with LPS and M14 is called an M9-administered group, and a group administered with LPS and M14 in combination is called an M14-administered group.
- the LPS-administered group showed enhanced expression of IL-6 mRNA. This reproduces the state of causing a cytokine storm.
- a decrease in the expression of IL-6 mRNA was confirmed in all of the mangiferin 8a-administered group, the noracliol-administered group, the M9-administered group, and the M14-administered group.
- Example 5 Effect of suppressing TNF ⁇ production in B cells Using mouse B cells, the inhibitory effect of compounds on TNF ⁇ production involved in cytokine storm was examined.
- Mouse B cells were cultured in RPMI1640 medium for one day. After that, 10 ⁇ M mangiferin 8a, 10 ⁇ M norachirol, 1 ⁇ M M9, and 1 ⁇ M M14 were added to the B cells, cultured for 1 day, 10 ⁇ g/mL LPS was added, and cultured for 2 days. After culturing for 2 days, the culture supernatant was collected and the amount of TNF ⁇ produced was measured by an enzyme-linked immunosorbent assay (ELISA). This measurement was performed using a mouse TNF ⁇ ELISA kit (R&D).
- ELISA enzyme-linked immunosorbent assay
- TNF ⁇ was 15.13 pg/mL, while in 10 ⁇ g/mL LPS, it was 296.31 pg/mL, indicating that LPS stimulation activates B cells and promotes TNF ⁇ secretion.
- the mangiferin 8a-administered group, the noracliol-administered group, the M9-administered group, and the M14-administered group significantly suppressed TNF ⁇ production upon LPS stimulation.
- Example 6 Effect of suppressing IL-6 production in B cells Using mouse B cells, suppression of IL-6 production involved in cytokine storm by compounds was examined.
- Mouse B cells were cultured in RPMI1640 medium for one day. After that, 10 ⁇ M mangiferin 8a, 10 ⁇ M norachirol, 1 ⁇ M M9, and 1 ⁇ M M14 were added to the B cells, cultured for 1 day, 10 ⁇ g/mL LPS was added, and cultured for 2 days. After culturing for 2 days, the culture supernatant was collected and IL-6 production was measured by enzyme-linked immunosorbent assay (ELISA). This measurement was performed using a mouse IL-6 ELISA kit (R&D).
- ELISA enzyme-linked immunosorbent assay
- the results are shown in Figure 6.
- the horizontal axis represents sample groups, and the vertical axis represents IL-6 production.
- IL-6 was 9.46 pg/mL, whereas in 10 ⁇ g/mL LPS, it was 246.13 pg/mL, indicating that LPS stimulation activates B cells and promotes IL-6 secretion. .
- Example 7 Effect of suppressing TNF ⁇ production in macrophages Using mouse macrophages, the inhibitory effects of compounds on TNF ⁇ production involved in cytokine storm were examined.
- Mouse macrophages were cultured in RPMI1640 medium for one day. After that, 10 ⁇ M mangiferin 8a, 10 ⁇ M noratilol, 1 ⁇ M M9, and 1 ⁇ M M14 were added to the macrophages, cultured for 1 day, 10 ⁇ g/mL LPS was added, and cultured for 2 days. After culturing for 2 days, the culture supernatant was collected and the amount of TNF ⁇ produced was measured by an enzyme-linked immunosorbent assay (ELISA). This measurement was performed using a mouse TNF ⁇ ELISA kit (R&D).
- ELISA enzyme-linked immunosorbent assay
- TNF ⁇ was 24.11 pg/mL, while in 10 ⁇ g/mL LPS, it was 421.13 pg/mL, indicating that LPS stimulation activates macrophages and promotes TNF ⁇ secretion.
- the mangiferin 8a-administered group, the noracliol-administered group, the M9-administered group, and the M14-administered group significantly suppressed TNF ⁇ production upon LPS stimulation.
- Example 8 Effect of suppressing IL-6 production in mouse macrophages Using mouse macrophages, suppression of IL-6 production involved in cytokine storm by compounds was examined.
- Mouse macrophages were cultured in RPMI1640 medium for one day. After that, 10 ⁇ M mangiferin 8a, 10 ⁇ M noratilol, 1 ⁇ M M9, and 1 ⁇ M M14 were added to the macrophages, cultured for 1 day, 10 ⁇ g/mL LPS was added, and cultured for 2 days. After culturing for 2 days, the culture supernatant was collected and IL-6 production was measured by enzyme-linked immunosorbent assay (ELISA). This measurement was performed using a mouse IL-6 ELISA kit (R&D).
- ELISA enzyme-linked immunosorbent assay
- IL-6 was 13.13 pg/mL in Control, whereas 321.13 pg/mL in 10 ⁇ g/mL LPS, indicating that LPS stimulation activates macrophages and promotes IL-6 secretion. On the other hand, it was 69.16 pg/mL, 64.13 pg/mL, 49.46 pg/mL, and 45.13 pg/mL in the mangiferin 8a-administered group, the norachillol-administered group, the M9-administered group, and the M14-administered group, respectively.
- Example 9 Effect of Compounds to Suppress Lethality in Cytokine Storm
- Six-week-old male C57BL/6J (Shimizu Experimental Materials) were orally given 50 mg/kg mangiferin 8a, 100 mg/kg norachiriol, 50 mg/kg M9, and 50 mg/kg M14. 5 minutes later, 25 mg/kg LPS was intraperitoneally administered.
- the administration start date was defined as day 0, and the survival rate was measured on day 2.
- a control group was administered with no compound or LPS, a LPS-administered group was administered with 25 mg/kg LPS, a group with 50 mg/kg mangiferin 8a and 25 mg/kg LPS was administered with mangiferin 8a, and a group with 100 mg/kg norachiriol and 25 mg/kg LPS were administered as norachirol-administered group, 50 mg/kg M9 and 25 mg/kg LPS were administered as M9-administered group, and 50 mg/kg M14 and 25 mg/kg LPS were administered as M14-administered group. call.
- Figure 9 shows the survival rate results.
- the horizontal axis indicates compound treatment, and the vertical axis indicates survival rate (%).
- “*” is shown for those that were significantly different from the control group (P ⁇ 0.05).
- the LPS-administered group showed a significant decrease in survival rate, indicating that the cytokine storm caused by LPS administration decreased the survival rate.
- the mangiferin 8a-administered group, the norachirol-administered group, the M9-administered group, and the M14-administered group significantly suppressed the decrease in survival rate.
- the mangiferin 8a-administered group, the noracliol-administered group, the M9-administered group, and the M14-administered group improved the mortality rate due to cytokine storm.
- TNF- ⁇ production inhibitory effect Six-week-old male C57BL/6J (Shimizu experimental materials) were orally administered with 100 mg/kg nolatyrol, 50 mg/kg M9, and 50 mg/kg M14, and 5 minutes later, 25 mg/kg LPS was intraperitoneally administered. Two hours after LPS administration, serum was collected from the mice, and TNF ⁇ production involved in cytokine storm was measured by enzyme-linked immunosorbent assay (ELISA). This measurement was performed using a mouse TNF ⁇ ELISA kit (R&D).
- ELISA enzyme-linked immunosorbent assay
- the control group was administered no compounds and LPS, the LPS-administered group was administered 25 mg/kg LPS, the group administered 100 mg/kg norachiriol and 25 mg/kg LPS, the norachiriol-administered group 50 mg/kg M9 and 25 mg /kg LPS was administered as the M9 administration group, and 50 mg/kg M14 and 25 mg/kg LPS as the M14 administration group.
- Fig. 10 The results are shown in Fig. 10.
- the horizontal axis represents sample groups, and the vertical axis represents TNF ⁇ production.
- TNF ⁇ was 1.55 ng/mL
- TNF ⁇ secretion was increased to 10.28 ng/mL, indicating that cytokine storm was caused.
- They were 2.71 ng/mL, 5.68 ng/mL, and 5.2 ng/mL in the noratilol-administered group, the M9-administered group, and the M14-administered group, respectively.
- the noratilol-administered group, the M9-administered group, and the M14-administered group markedly suppressed TNF ⁇ production related to cytokine storm even in vivo.
- IL-6 production inhibitory effect Six-week-old male C57BL/6J (Shimizu experimental materials) were orally administered with 100 mg/kg nolatyrol, 50 mg/kg M9, and 50 mg/kg M14, and 5 minutes later, 25 mg/kg LPS was intraperitoneally administered. Serum was collected from the mice 2 hours after LPS administration, and IL-6 production involved in cytokine storm was measured by enzyme-linked immunosorbent assay (ELISA). This measurement was performed using a mouse IL-6 ELISA kit (R&D).
- ELISA enzyme-linked immunosorbent assay
- the control group was administered no compounds and LPS, the LPS-administered group was administered 25 mg/kg LPS, the group administered 100 mg/kg norachiriol and 25 mg/kg LPS, the norachiriol-administered group 50 mg/kg M9 and 25 mg
- the group administered 50 mg/kg M14 and 25 mg/kg LPS is called the M14 administration group.
- Fig. 11 The horizontal axis represents sample groups, and the vertical axis represents IL-6 production. While IL-6 was 2.75 ng/mL in the control, 10 ⁇ g/mL LPS increased IL-6 secretion to 20.1 ng/mL, indicating that it caused a cytokine storm. They were 11.37 ng/mL, 15.15 ng/mL, and 14.26 ng/mL in the noratilol-administered group, the M9-administered group, and the M14-administered group, respectively.
- the noratilol-administered group, the M9-administered group, and the M14-administered group markedly suppressed IL-6 production related to cytokine storm in vivo.
- the cytokine storm inhibitor according to the present invention is COVID-19, cytokine release syndrome, cytokine release syndrome due to CAR-T therapy, sepsis, systemic inflammatory response syndrome, hemophagocytic syndrome, macrophage activation syndrome, influenza, GVHD, systemic It is possible to provide a therapeutic drug for cytokine storm, which is one of the causes of death such as vasculitis, Kawasaki disease, and Takayasu arteritis.
- cytokine release syndrome COVID-19, cytokine release syndrome, cytokine release syndrome due to CAR-T therapy, sepsis, systemic inflammatory response syndrome, hemophagocytic syndrome, macrophage activation syndrome, influenza, GVHD, systemic vasculitis, Kawasaki disease, Takayasu artery Fulminant pneumonia other than inflammation, fulminant respiratory failure, fulminant hepatitis, fulminant myocarditis, fulminant colitis, fulminant sepsis, fulminant malaria, fulminant antiphospholipid antibody syndrome, fulminant It can also be used as a therapeutic drug for fulminant inflammation caused by fulminant pancreatitis, fulminant meningococcemia, fulminant type 1 diabetes, fulminant mutant collagen disease, and disseminated intravascular coagulation.
- cytokine release syndrome COVID-19, cytokine release syndrome, cytokine release syndrome due to CAR-T therapy, sepsis, systemic inflammatory response syndrome, hemophagocytic syndrome, macrophage activation syndrome, influenza, GVHD, systemic vasculitis, Kawasaki disease, Takayasu arteritis Improving the cytokine storm caused by such factors will also improve the patient's survival rate. Furthermore, since the cytokine storm inhibitor according to the present invention can be administered orally, it contributes to the improvement of the tight medical field.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
(a)マンギフェリンから中間物質M7を合成する。
(b)中間物質M7からマンギフェリン8a((2)式)を合成する。
(c)マンギフェリン8aからM9((3)式)を合成する。
(d)マンギフェリンから中間物質M11を合成する。
(e)中間物質M11から中間物質M12を合成する。
(f)中間物質M12からM14((4式))を合成する。
(g)ノラチリオール((1式))を合成する。
マンギフェリン(4.21g,10.0mmol)、無水プロピオン酸(19.2mL,149mmol)、DMAP(122mg,1mmol)および乾燥ピリジン(60mL)を100℃で24時間加熱した。反応液を氷水(600mL)に注加し、酢酸エチルで抽出した。酢酸エチル層を氷冷した10%硫酸、飽和炭酸水素ナトリウム水溶液および飽和食塩水で順次洗浄後、無水硫酸ナトリウムで乾燥後、ろ過、濃縮した。残渣をカラムクロマトグラフィー(n-ヘキサン/酢酸エチル=1/1)を用いて精製し,標題化合物(7.19g、83%)を無色固体として得た。
IR (KBr): 1774, 1755, 1667, 1620, 1458, 1354, 1273, 1157, 1114, 1083 cm-1. 1H NMR (800 MHz, DMSO-d6, 25 °C) δ: 0.71-0.77/0.93-0.97 (each 3H, m, COCH2CH3), 0.98-1.02/1.12-1.16/1.19-1.28 (each 6H, m, COCH2CH3), 1.92-2.01 (2H, m, COCH2CH3), 2.17-2.32 (6H, m, COCH2CH3), 2.60-2.94 (8H, m, COCH2CH3), 3.86-3.92 (1H, m, H-6’a), 4.21-4.30 (2H, m, H-5’ and H-6’b), 5.01-5.06 (1H, m, H-4’), 5.10-5.20 (1H, m, H-1’), 5.45-5.53 (2H, m, H-2’ and H-3’), 7.51/7.53 (1H, each s, H-4), 7.68/7.69 (1H, each s, H-5), 7.97/7.98 (1H, each s, H-8). 13C NMR (200 MHz, DMSO-d6 25 °C) δ: 8.64/8.75/8.77/8.91/8.94/8.96/9.00/9.13/9.16 (COCH2CH3), 26.58/26.63/26.7/26.8/26.89/26.94/27.0/27.1/27.32/27.34 (COCH2CH3), 62.1/62.2 (C6’), 68.18/68.20 (C4’), 69.6/70.0 (C2’), 70.8/71.3 (C1’), 73.5/73.6 (C3’), 75.0/75.1 (C5’), 110.2/111.8 (C4), 111.6/112.7 (C9a), 113.2/113.3 (C5), 118.8/118.9 (C2), 119.6/119.7 (C8a), 120.3/120.4 (C8), 139.5/139.6 (C7), 147.9 (C6), 149.1/150.9 (C1), 152.47/152.51 (C8b), 153.4/154.8 (C4a), 156.5/156.8 (C3), 170.9/171.04/171.06/171.09/171.67/171.72/171.9/172.4/172.6/172.7/173.18/173.22/173.51/173.54 (COCH2CH3), 173.1 (C9). HRMS (ESI) m/z: [M+Na]+ Calcd for C43H50O19Na 893.2839; Found 893.2853.以上であった。
中間物質M7の構造を(6)式に示す。
マンギフェリン8aは、以下のようにして合成した。1,3,2’,3’,4’,6,6’,7-オクタ-O-プロピオニルマンギフェリン(M7)(5.06g,5.68mmol)、酢酸アンモニウム(6.7g,87.0mmol)、メタノール(160mL)および水(20mL)の混合溶液を室温で6時間撹拌した。反応液から減圧濃縮によりメタノールを留去した後、残渣を酢酸エチル(100mL)で希釈した。その混合物を、水および飽和食塩水で順次洗浄後、無水硫酸ナトリウムで乾燥後、ろ過、濃縮した。残渣をカラムクロマトグラフィー[CHCl3/CH3OH(20:1)]を用いて精製し、標題化合物(3.89g 95%)を淡黄色固体として得た。マンギフェリン8aは(2)式で表される。
IR (KBr): 3406, 1751, 1620, 1462, 1354, 1284, 1192, 1083 cm-1. 1H NMR (800 MHz, DMSO-d6, 25 °C) δ: 0.74/0.94 (each 3H, t-like, J = 7.6, COCH2CH3), 0.97-1.02 (6H, m, COCH2CH3), 1.20/1.23 (each 1.5H, t-like, J = 7.6, COCH2CH3), 1.92-2.02 (2H, m, COCH2CH3), 2.15-2.33 (6H, m, COCH2CH3), 2.61-2.86 (2H, m, COCH2CH3), 3.85 (0.5H, dd-like, J = ca. 12.5, 1.9, H-6a’), 4.05 (0.5H, br d-like, J = ca. 12.5, H-6a’), 4.07 (0.5H, ddd, J = 9.8, 4.7, 1.9, H-5’), 4.09-4.14 (0.5H, m, H-6b’), 4.11 (0.5H, br d-like, J = ca. 9.5, H-5’), 4.24 (0.5H, dd, J = 12.5, 4.7, H-6b’), 4.96 (0.5H, d, J = 9.9, H-1’), 5.00 (0.5H, dd, J = 9.5, 9.5, H-4’), 5.02 (0.5H, dd, J = 9.8, 9.8, H-4’), 5.16 (0.5H, d, J = 10.0, H-1’), 5.35 (0.5H, dd, J = 9.5, 9.5, H-3’), 5.40 (0.5H, dd, J = 9.8, 9.5, H-3’), 5.49 (0.5H, dd, J = 10.0, 9.5, H-2’), 5.84 (0.5H, dd, J = 9.9, 9.5, H-2’), 6.72/6.75 (each 0.5H, s, H-4), 6.80/6.81 (each 0.5H, s, H-5), 7.29/7.30 (each 0.5H, s, H-8), 9.62/10.5 (each 1H, br s, OH), 11.2/11.4 (each 0.5H, br s, OH). 13C NMR (200 MHz, DMSO-d6, 25 °C) δ: 8.81/8.86/8.96/9.02/9.06/9.11/9.12/9.20 (COCH2CH3), 26.6/26.89/26.91/26.94/27.00/27.04/27.1/27.4 (COCH2CH3), 62.1/62.3 (C-6’), 68.2/68.3 (C-4’), 68.7/70.4 (C-2’), 71.0/71.1 (C-1’), 73.8/74.1 (C-3’), 74.6/75.2 (C-5’), 99.5/100.8 (C-4), 102.5 (C-5), 106.6/107.8 (C-9a), 109.1 (C-8), 113.3 (C-2), 114.0/114.1 (C-8a), 143.8 (C-7), 149.77/149.82 (C-6, C-1), 151.3 (C-1), 153.3 (C-8b), 157.5/157.7 (C-4a), 160.7/162.2 (C-3), 171.1/171.9/172.2/172.5/172.8/173.1/173.4/173.6 (COCH2CH3) 172.68/172.71 (C-9). HRMS (ESI) m/z: [M-H]- Calcd for C34H37O16 701.2076; Found 701.2070.以上であった。
1,2’,3’,4’,6-ペンタ-O-プロピオニルマンギフェリン(マンギフェリン8a)(3.88g,5.52mmol)、N,N-ジメチルトリメチレンジアミン(3.47mL,27.6mmol)およびDMSO(40mL)の混合物を室温で1時間撹拌した。反応液を氷水(500mL)に注加し、ジエチルエーテルおよびヘキサンの混合溶液(3/1)で抽出した。有機層を飽和食塩水で洗浄、無水硫酸ナトリウムで乾燥後、ろ過、濃縮した。残渣をカラムクロマトグラフィー[CHCl3/CH3OH(20:1)]を用いて精製し、標題化合物(3.08g,86%)を淡黄色固体として得た。M9の構造は(3)式で表される。
IR (KBr): 3399 1751, 1618, 1475, 1292, 1190, 1084 cm-1. 1H NMR (800 MHz, DMSO-d6, 60 °C) δ: 0.74/0.97/1.02/1.03 (each 3H, t, J = 7.6, COCH2CH3), 1.95/1.98 (each 1H, dq, J = 16.5, 7.6, COCH2CH3), 2.18 (2H, q, J = 7.6, COCH2CH3), 2.22-2.34 (4H, m, COCH2CH3), 3.99 (1H, ddd-like, J = 9.8, 4.5, 2.5, H-5’), 4.10 (1H, dd, J = 12.5, 2.5, H-6a’), 4.12 (1H, dd, J = 12.5, 4.5, H-6b’), 5.06 (1H, dd, J = 9.8, 9.8, H-4’), 5.10 (1H, d, J = 10.0, H-1’), 5.31 (1H, dd, J = 9.8, 9.5, H-3’), 5.85 (1H, br dd, J = 10.0, 9.5, H-2’), 6.35 (1H, s, H-4), 6.85 (1H, s, H-4), 7.34 (1H, s, H-8), 9.0-11.0 (3H, br, OH), 13.9 (1H, s, OH). 13C NMR (200 MHz, DMSO-d6, 60 °C) δ: 8.71/8.79/8.82 (COCH2CH3), 26.72/26.73/ 26.77/26.83 (COCH2CH3), 62.0 (C-6’), 68.3 (C-4’), 69.1 (C-2’), 70.4 (C-1’), 74.2 (C-3’), 75.0 (C-5’), 93.3 (C-4), 101.0 (C-9a), 102.6 (C-5), 104.2 (C-2), 108.2 (C-8), 111.7 (C-8a), 143.8 (C-7), 150.8 (C-6), 154.2 (C-8b), 156.8 (C-4a), 161.9 (C-1), 163.6 (C-3), 171.9/172.5/172.7/173.1 (COCH2CH3) 179.0 (C-9). HRMS (ESI) m/z: [M-H]- Calcd for C31H33O15 645.1814; Found 645.1817.以上であった。
中間物質M7の製造方法で、無水プロピオン酸を無水酪酸に置き換えたほかは、中間物質M7の合成方法に従い合成した。収率は81%であった。
無色固体: IR (KBr): 1775, 1751, 1665, 1618, 1458, 1157, 1092 cm-1. 1H NMR (800 MHz, DMSO-d6, 25 °C) δ: 0.52-1.11 (24H, m, COCH2CH2CH3), 1.20-1.97 (16H, m, COCH2CH2CH3), 2.14-2.88 (16H, m, COCH2CH2CH3), 3.88-3.94 (1H, m, H-6’a), 4.16-4.25 (2H, m, H-5’ and H-6’b), 5.02-5.06 (1H, m, H-4’), 5.06-5.12 (1H, m, H-1’), 5.45-5.52 (1H, m, H-3’), 5.54-5.65 (1H, m, H-2’), 7.50/7.53 (1H, each s, H-4), 7.68/7.69 (1H, each s, H-5), 7.95/7.96 (1H, each s, H-8). 13C NMR (200 MHz, DMSO-d6 25 °C) δ: 13.1/13.41/13.45/13.48/13.51/13.58/13.64/13.8 (COCH2CH2CH3), 17.5/17.62/17.66/17.72/17.76/17.83/17.88/17.90 (COCH2CH2CH3), 34.9/35.09/35.15/35.17/35.19/35.31/35.33/35.4/35.68/35.73 (COCH2CH2CH3), 62.0/62.2 (C6’), 68.2/68.3 (C4’), 69.3/69.8 (C2’), 70.9/71.3 (C1’), 73.36/73.43 (C3’), 75.1/75.2 (C5’), 110.2/111.6 (C4), 111.6/112.6 (C9a), 113.3/113.4 (C5), 118.7/118.8 (C2), 119.6/119.7 (C8a), 120.35/120.40 (C8), 139.5 (C7), 147.82/147.85 (C6), 149.1/150.8 (C1), 152.46/152.49 (C8b), 153.4/154.7 (C4a), 156.6/156.8 (C3), 169.9/170.14/170.17/170.18/170.7/170.8/171.0/171.4/171.6/171.8/172.0/172.1/172.5/172.6 (COCH2CH3), 173.1 (C9). HRMS (ESI) m/z: [M+Na]+ Calcd for C51H67O19Na 1005.4091; Found 1005.4092.以上であった。
中間物質M11の構造は(7)式のようになる。
8aの合成方法において、1,3,2’,3’,4’,6,6’,7-オクタ-O-プロピオニルマンギフェリン(M7)に変えて、1,3,2’,3’,4’,6,6’,7-オクタ-O-ブチリルマンギフェリン(M11)を出発材とした他は、M8の合成方法に従って合成した。収率は93%であった。
淡かっ色固体: IR (KBr): 3385, 1751, 1624, 1458, 1288, 1188, 1099 cm-1. 1H NMR (800 MHz, DMSO-d6, 25 °C) δ: 0.48-1.09 (15H, m, COCH2CH2CH3), 1.18-1.83 (10H, m, COCH2CH2CH3), 1.89-2.86 (10H, m, COCH2CH2CH3), 3.87 (0.5H, dd-like, J = ca. 12.6, 1.6, H-6a’), 4.02-4.11 (2H, br m, , H-5, H-5’, H-6a’, H-6b’), 4.16 (0.5H, dd, J = 12.6, 4.8, H-6b’), 4.90 (0.5H, d, J = 9.6, H-1’), 5.01 (0.5H, dd, J = 9.6, 9.6, H-4’), 5.02 (0.5H, dd, J = 9.6, 9.6, H-4’), 5.15 (0.5H, d, J = 10.4, H-1’), 5.35 (0.5H, dd, J = 9.6, 9.6, H-3’), 5.37 (0.5H, br dd-like, J = ca. 9.6, 9.6, H-3’), 5.54 (0.5H, dd, J = 10.4, 9.6, H-2’), 5.88 (0.5H, br dd-like, J = ca. 9.6, 9.6, H-2’), 6.72/6.74 (each 0.5H, s, H-4), 6.797/6.803 (each 0.5H, s, H-5), 7.29/7.30 (each 0.5H, s, H-8), 9.67/10.5/11.2 (each 1H, br s, OH). 13C NMR (200 MHz, DMSO-d6, 25 °C) δ: 13.1/13.4/13.50/13.54/13.6/13.7/13.9 (COCH2CH2CH3), 17.7/17.90/17.93/17.96/18.02 (COCH2CH2CH3), 35.1/35.2/35.3/35.37/35.41/35.46/35.50/35.54/35.9 (COCH2CH2CH3), 62.0/62.4 (C-6’), 68.2/68.4 (C-4’), 68.5/70.3 (C-2’), 71.1/71.2 (C-1’), 73.7/74.0 (C-3’), 74.9/75.3 (C-5’), 99.7/100.8 (C-4), 102.52/102.54 (C-5), 106.6/107.8 (C-9a), 109.1 (C-8), 113.2/113.4 (C-2), 114.06/114.08 (C-8a), 143.9 (C-7), 149.8/149.9 (C-6, C-1), 151.3 (C-1), 153.3 (C-8b), 157.6/157.7 (C-4a), 160.9/162.3 (C-3), 170.3/171.1/171.2/171.5/171.9/172.2/172.6 (COCH2CH3) 172.7 (C-9). HRMS (ESI) m/z: [M-H]- Calcd for C39H47O16 771.2859; Found 771.2858.以上であった。
中間物質M12の構造は(8)式のようになる。
M9の合成方法において、1,3,2’,3’,4’,6,6’,7-オクタ-O-プロピオニルマンギフェリン(マンギフェリン8a)に変えて、1,2’,3’,4’,6-ペンタ-O-ブチリルマンギフェリン(M12)を出発材とした他は、M9の合成方法に従って合成した。収率は84%であった。
淡黄色固体:IR (KBr): 3399 1751, 1618, 1474, 1292, 1188, 1085 cm-1. 1H NMR (800 MHz, DMSO-d6, 60 °C) δ: 0.50 (3H, br, t-like J = ca. 7.0, COCH2CH2CH3), 0.83/0.871/0.872 (each 3H, t, J = 7.4, COCH2CH2CH3), 1.18-1.30/1.44-1.49 (each 2H, m, COCH2CH2CH3), 1.50-1.56 (6H, m, COCH2CH2CH3), 1.93 (2H, t, J = 7.0, COCH2CH2CH3), 2.15 (2H, t, J = 7.2, COCH2CH2CH3), 2.22-2.31 (4H, m, COCH2CH2CH3), 3.98 (1H, ddd-like, J = 9.8, 4.6, 2.5, H-5’), 4.09 (1H, dd, J = 12.5, 4.6, H-6a’), 4.11 (1H, dd, J = 12.5, 2.5, H-6b’), 5.06 (1H, dd, J = 9.8, 9.8, H-4’), 5.09 (1H, d, J = 10.0, H-1’), 5.31 (1H, dd, J = 9.8, 9.5, H-3’), 5.85 (1H, br dd, J = 10.0, 9.5, H-2’), 6.34 (1H, s, H-4), 6.85 (1H, s, H-4), 7.38 (1H, s, H-8), 8.9-11.5 (3H, br, OH), 13.9 (1H, s, OH). 13C NMR (200 MHz, DMSO-d6, 60 °C) δ: 12.6/13.13/13.16/13.22 (COCH2CH2CH3), 17.62/17.64/17.66 (COCH2CH2CH3), 35.16/35.23/35.26/35.31 (COCH2CH2CH3), 61.9 (C-6’), 68.3 (C-4’), 69.0 (C-2’), 70.4 (C-1’), 74.1 (C-3’), 75.0 (C-5’), 93.3 (C-4), 101.1 (C-9a), 102.6 (C-5), 104.2 (C-2), 108.2 (C-8), 111.7 (C-8a), 143.8 (C-7), 150.8 (C-6), 154.2 (C-8b), 156.8 (C-4a), 162.1 (C-1), 163.7 (C-3), 170.9/171.6/171.7/172.3 (COCH2CH3) 179.0 (C-9). HRMS (ESI) m/z: [M-H]- Calcd for C35H41O15 701.2440; Found 701.2440.以上であった。
ノラチリオールを非特許文献1の方法に従って合成した。なお、ノラチリオールはCAS番号3542-72-1で表される既知物質であり、市販もされているので、購入してもよい。
(1)2,4,5-トリメトキシ安息香酸クロリド(化合物III)の製造方法
2,4,5-トリメトキシ安息香酸(化合物II、8.49g、0.040mol)にアルゴン雰囲気下、室温で塩化チオニル(5mL)を徐々に加えて溶解させたのち、6時間加熱還流を行った。反応終了後、反応混合物を減圧下留去し、2,4,5-トリメトキシ安息香酸クロリド(化合物III、8.30g、90%)を得た。得られた化合物(III)は、ただちに次の反応へ用いた。
上述のようにして得られた2,4,5-トリメトキシ安息香酸クロリド(化合物III、8.07g、0.035mol)、1,3,5-トリメトキシベンゼン(化合物IV、6.48g、0.0385mol)および無水ジエチルエーテル(500mL)の混合懸濁物にアルゴン雰囲気下、室温で塩化アルミニウム(16g)を徐々に加えた後、反応混合物を室温で48時間攪拌した。反応液を減圧下溶媒留去した後、残渣に水を加え、酢酸エチルにて抽出した。抽出液を飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥し、ひだ折りろ紙にて乾燥剤を濾別後、ろ液を減圧下溶媒留去して粗生成物を得た。得られた粗生成物をシリカゲルカラムクロマトグラフィー(n-ヘキサン:酢酸エチル=1:1,v/v)により精製し、2-ヒロドキシ-2’,4,4’,5,6’-ペンタメトキシベンゾフェノン(化合物V、8.43g、69%)を得た。
上述のようにして得られた2-ヒロドキシ-2’,4,4’,5,6’-ペンタメトキシベンゾフェノン(化合物V、6.97g、0.020mol)をピリジン(10mL)と水(10mL)との混合溶媒を溶かし、40%テトラブチルアンモニウムヒドロキシド水溶液(5mL)を加えて6時間加熱還流を行った。得られた反応混合物を5%塩酸に注加した後、酢酸エチルで抽出した。抽出液を飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥し、ひだ折りろ紙にて乾燥剤を濾別後、ろ液を減圧下溶媒留去して粗生成物を得た。得られた粗生成物をシリカゲルカラムクロマトグラフィー(n-ヘキサン:酢酸エチル=1:1,v/v)により精製し、1,3,6,7-テトラメトキシキサントン(化合物VI、5.82g、92%)を得た。
上述のようにして得られた1,3,6,7-テトラメトキシキサントン(化合物VI、4.74g、0.015mol)とピリジン塩酸塩(5.00g)の混合物を6時間、200℃にて加熱攪拌した。得られた反応混合物を室温まで放冷後、5%塩酸に注加した後、酢酸エチルで抽出した。抽出液を飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥し、ひだ折りろ紙にて乾燥剤を濾別後、ろ液を減圧下溶媒留去して粗生成物を得た。得られた粗生成物をシリカゲルカラムクロマトグラフィー(クロロホルム:メタノール=7:1,v/v)により精製し、(2)式のノラチリオール(化合物I、2.65g、68%)を得た。
マウスB細胞を用いてサイトカインストームに関与するTNFα mRNA発現に対する化合物の抑制の検討を行った。
マウスB細胞を用いてサイトカインストームに関与するIL-6 mRNA発現に対する化合物の抑制の検討を行った。実験手順は実施例1と同じである。結果を図2に示す。
マウスマクロファージを用いてサイトカインストームに関与するTNFα mRNA発現に対する化合物の抑制の検討を行った。
マウスマクロファージを用いてサイトカインストームに関与するIL-6 mRNA発現に対する化合物の抑制の検討を行った。
マウスB細胞を用いてサイトカインストームに関与するTNFα産生に対する化合物の抑制の検討を行った。
マウスB細胞を用いてサイトカインストームに関与するIL-6産生に対する化合物の抑制の検討を行った。
マウスマクロファージを用いてサイトカインストームに関与するTNFα産生に対する化合物の抑制の検討を行った。
マウスマクロファージを用いてサイトカインストームに関与するIL-6産生に対する化合物の抑制の検討を行った。
6週齢のオスC57BL/6J(清水実験材料)に50mg/kg マンギフェリン8a、100mg/kg ノラチリオール、50mg/kg M9、50mg/kg M14を経口投与し、その5分後に25mg/kg LPS腹腔内投与した。なお、投与開始日を0日目とし、2日目の生存率を測定した。
6週齢のオスC57BL/6J(清水実験材料)に100mg/kg ノラチリオール、50mg/kg M9、50mg/kg M14を経口投与し、その5分後に25mg/kg LPS腹腔内投与した。LPS投与2時間後にマウスから血清を採取し、酵素結合免疫吸着測定法(ELISA)によってサイトカインストームに関与するTNFα産生量を測定した。この測定にはマウスTNFα ELISAキット(R&D)を用いて行った。
6週齢のオスC57BL/6J(清水実験材料)に100mg/kg ノラチリオール、50mg/kg M9、50mg/kg M14を経口投与し、その5分後に25mg/kg LPS腹腔内投与した。LPS投与2時間後にマウスから血清を採取し、酵素結合免疫吸着測定法(ELISA)によってサイトカインストームに関与するIL-6産生量を測定した。この測定にはマウスIL-6 ELISAキット(R&D)を用いて行った。
Claims (5)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/276,114 US20240115589A1 (en) | 2021-02-15 | 2022-02-14 | Pharmaceutical composition for preventing cytokine storm |
JP2022580708A JPWO2022173042A1 (ja) | 2021-02-15 | 2022-02-14 | |
EP22752864.3A EP4292593A1 (en) | 2021-02-15 | 2022-02-14 | Pharmaceutical composition for preventing cytokine storm |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021021955 | 2021-02-15 | ||
JP2021-021955 | 2021-02-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022173042A1 true WO2022173042A1 (ja) | 2022-08-18 |
Family
ID=82838365
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/005709 WO2022173042A1 (ja) | 2021-02-15 | 2022-02-14 | サイトカインストーム抑制用医薬組成物 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20240115589A1 (ja) |
EP (1) | EP4292593A1 (ja) |
JP (1) | JPWO2022173042A1 (ja) |
WO (1) | WO2022173042A1 (ja) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012020953A (ja) | 2010-07-13 | 2012-02-02 | Chiba Univ | 劇症型炎症の予防および/または治療剤 |
WO2016104436A1 (ja) | 2014-12-22 | 2016-06-30 | 国立大学法人 岡山大学 | サイトカインストーム抑制剤 |
WO2020130102A1 (ja) * | 2018-12-19 | 2020-06-25 | 学校法人近畿大学 | 自己免疫疾患の改善用組成物 |
WO2020162638A1 (ja) * | 2019-02-08 | 2020-08-13 | 学校法人近畿大学 | 悪性腫瘍疾患の改善用組成物 |
-
2022
- 2022-02-14 EP EP22752864.3A patent/EP4292593A1/en active Pending
- 2022-02-14 US US18/276,114 patent/US20240115589A1/en active Pending
- 2022-02-14 WO PCT/JP2022/005709 patent/WO2022173042A1/ja active Application Filing
- 2022-02-14 JP JP2022580708A patent/JPWO2022173042A1/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012020953A (ja) | 2010-07-13 | 2012-02-02 | Chiba Univ | 劇症型炎症の予防および/または治療剤 |
WO2016104436A1 (ja) | 2014-12-22 | 2016-06-30 | 国立大学法人 岡山大学 | サイトカインストーム抑制剤 |
WO2020130102A1 (ja) * | 2018-12-19 | 2020-06-25 | 学校法人近畿大学 | 自己免疫疾患の改善用組成物 |
WO2020162638A1 (ja) * | 2019-02-08 | 2020-08-13 | 学校法人近畿大学 | 悪性腫瘍疾患の改善用組成物 |
Non-Patent Citations (9)
Title |
---|
"Molecular theory of organic pharmaceuticals", 25 August 2012, KYOTO HIROKAWA SHOTEN, JP, ISBN: 978-4-901789-81-3, article SATOSHI SHUTO: "4) Prodrugs", pages: 169 - 171, XP009539019 * |
CAS, no. 3542-72-1 |
CHOWDHURY APU, LU JIHONG, ZHANG RUMENG, NABILA JAHAN, GAO HANG, WAN ZHIKANG, ADELUSI TEMITOPE ISAAC, YIN XIAOXING, SUN YING: "Mangiferin ameliorates acetaminophen-induced hepatotoxicity through APAP-Cys and JNK modulation", BIOMEDICINE & PHARMACOTHERAPY, ELSEVIER, FR, vol. 117, 1 September 2019 (2019-09-01), FR , pages 109097, XP055958598, ISSN: 0753-3322, DOI: 10.1016/j.biopha.2019.109097 * |
CONVERTINO IRMA, TUCCORI MARCO, FERRARO SARA, VALDISERRA GIULIA, CAPPELLO EMILIANO, FOCOSI DANIELE, BLANDIZZI CORRADO: "Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients", CRITICAL CARE, vol. 24, no. 1, 1 December 2020 (2020-12-01), XP055879485, DOI: 10.1186/s13054-020-03020-3 * |
GU TINGXUAN, ZHAO SIMIN, JIN GUOGUO, SONG MENGQIU, ZHI YAFEI, ZHAO RAN, MA FAYANG, ZHENG YAQIU, WANG KEKE, LIU HUI, XIN MINGXIA, H: "Cytokine Signature Induced by SARS-CoV-2 Spike Protein in a Mouse Model", FRONTIERS IN IMMUNOLOGY, vol. 11, 28 January 2021 (2021-01-28), XP055877307, DOI: 10.3389/fimmu.2020.621441 * |
HU LWU WCHAI XLUO JWU Q, BIOORG. MED. CHEM. LETT, vol. 21, 2011, pages 4013 - 4015 |
JI-SUN SHIN, YOUNG-SU NOH , DONG-HYUN KIM , YOUNG-WUK CHO , KYUNG-TAE LEE: "Mangiferin isolated from the rhizome of Anemarrhena asphodeloides inhibits the LPS-induced nitric oxide and prostagladin E2 via the NF-κB inactivation in inflammatory macrophages.", NATURAL PRODUCT SCIENCES, vol. 14, no. 3, 1 January 2008 (2008-01-01), pages 206 - 213, XP055958595 * |
QU SHIHUI; WANG WENQING; LI DEPENG; LI SHUMIN; ZHANG LIKE; FU YUNHE; ZHANG NAISHENG: "Mangiferin inhibits mastitis induced by LPS via suppressing NF-ĸB and NLRP3 signaling pathways", INTERNATIONAL IMMUNOPHARMACOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 43, 14 December 2016 (2016-12-14), NL , pages 85 - 90, XP029881743, ISSN: 1567-5769, DOI: 10.1016/j.intimp.2016.11.036 * |
WILZ, S. W.: "A clinical trial of IL-15 and IL-21 combination therapy for COVID-19 is warranted. ", CYTOKINE & GROWTH FACTOR REVIEWS, ELSEVIER LTD, GB, vol. 58, 1 August 2020 (2020-08-01), GB , pages 49 - 50, XP055958605, ISSN: 1359-6101, DOI: 10.1016/j.cytogfr.2020.06.008 * |
Also Published As
Publication number | Publication date |
---|---|
JPWO2022173042A1 (ja) | 2022-08-18 |
EP4292593A1 (en) | 2023-12-20 |
US20240115589A1 (en) | 2024-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020162638A1 (ja) | 悪性腫瘍疾患の改善用組成物 | |
WO2020130102A1 (ja) | 自己免疫疾患の改善用組成物 | |
JPWO2004096198A1 (ja) | 治療剤 | |
KR100704299B1 (ko) | 신규한 퀴놀린계 화합물, 및 지네 추출물 또는 이로부터 분리된 화합물을 포함하는 심장순환계 질환의 예방 및 치료용 조성물 | |
CA2525486C (en) | Composition for lowering the internal lipid | |
JP2006273741A (ja) | PPARγリガンド活性を有する組成物 | |
JP6157041B2 (ja) | PPARγ活性化剤、抗肥満剤及び抗糖尿病剤 | |
JP5275315B2 (ja) | 新規化合物及びβ−セクレターゼ阻害剤 | |
JPWO2005074906A1 (ja) | 治療剤 | |
WO2012008467A1 (ja) | axial-equatorial aryl配向のfurofuran型リグナンを含有する骨形成促進用医薬組成物、その組成物を含有する医薬製剤、その組成物を含む機能性食品及び健康食品 | |
WO2022173042A1 (ja) | サイトカインストーム抑制用医薬組成物 | |
WO2022138735A1 (ja) | 悪性腫瘍疾患の改善用医薬組成物 | |
KR102287236B1 (ko) | 카탈폴 유도체 화합물을 포함하는 항암 보조제 | |
JP4993969B2 (ja) | 抗発癌プロモーター活性剤 | |
KR102203163B1 (ko) | 산꼬리풀 추출물 또는 그의 분획물을 포함하는 항암 보조제 | |
JP2021054838A (ja) | オレアノール酸アセテートを有効成分として含む、薬剤により誘発される腎臓毒性の予防、改善または治療用の組成物 | |
JP2017530110A (ja) | シュードリシマキオン・ロツンダム変種スブインテグルムから単離された新規の化合物(ks513)、その化合物を有効成分として含む、アレルギー性疾患、炎症性疾患、喘息又は慢性閉塞性肺疾患の予防又は治療用組成物及びその使用 | |
JP6368270B2 (ja) | モニエロサイドa及びその誘導体、又はそれを有効成分として含有する医薬用組成物、健康食品又は化粧品 | |
CN108904481B (zh) | 邻羟基查尔酮类似物在制备抗氧化药物中的应用 | |
JP2018177738A (ja) | Trpv4活性抑制剤 | |
JP2006348003A (ja) | マスト細胞IgEレセプター発現抑制剤 | |
JP5186084B2 (ja) | ロボフルーツ含有サポニンとその用途 | |
KR102482984B1 (ko) | 베타-펠토보이키놀산을 포함하는 폐섬유화증 및 미세먼지 관련 질환의 예방 또는 치료용 약학적 조성물 | |
WO1999004777A1 (fr) | Carcinostatiques | |
JPWO2004009521A1 (ja) | 治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22752864 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022580708 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18276114 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022752864 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022752864 Country of ref document: EP Effective date: 20230915 |